DelMar Pharmaceuticals Announces Approval for Listing on NASDAQ

DelMar Pharmaceuticals (OTCQX:DMPID) announced today that it has received approval from the Nasdaq Stock Market LLC  for the listing of its common stock on the NASDAQ Capital Market.
As quoted in the press release:

DelMar’s common stock will begin trading on the NASDAQ Capital Market at the opening of trading on Tuesday, July 12, 2016 under the ticker symbol DMPI.  The Company’s common stock will continue to trade on the OTCQX exchange until the market close on June 11, 2016.
In honor of the listing, the Company will ring the Opening Bell at the NASDAQ MarketSite in Times Square, New York City, on Thursday, July 14, 2016 (link to live webcast beginning at 9:20 am ET)

DelMar Pharmaceuticals Chairman and CEO, Jeffrey Bacha, stated:

Our listing on the NASDAQ marks the achievement of a major corporate milestone for our Company and is a testament to the progress that our team has made over the past few years. We believe that listing on NASDAQ will position us to broaden our shareholder base, increase appeal to institutional investors, provide improved liquidity and ultimately contribute to increasing shareholder value.

Connect with DelMar Pharmaceuticals (OTCQX:DMPID) to receive an Investor Presentation.